Equity Profile

CORT

Corcept Therapeutics Incorporated

Health CarePharmaceuticals$12.0B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Corcept Therapeutics Incorporated is a pharmaceutical company focused on developing and commercializing drugs that treat disorders related to cortisol, a stress hormone. With a market cap of $12 billion, Corcept plays a significant role in the healthcare sector, particularly in addressing conditions like Cushing's syndrome and certain types of cancer.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will help gauge the company's financial health this quarter.

0.36

Revenue

Total revenue reflects the company's sales performance and growth potential, which is critical for investor confidence.

300M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CORT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.94%

Avg Stock Reaction

-0.00%

Last Quarter Recap

In Q1 2026, Corcept reported an EPS of -0.30, matching analyst expectations but showing no revenue figures. The stock reacted slightly negatively, declining by 0.15% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Corcept's upcoming earnings, with expectations for a modest profit and steady revenue growth.

Bull Case

If Corcept beats the EPS estimate and shows strong revenue growth, it could signal robust demand for its products, boosting investor confidence.

Bear Case

Conversely, if the company misses earnings expectations again, it could raise concerns about its growth trajectory and profitability.

Key Metrics to Watch

EPS

0.36

Earnings per share is a key indicator of profitability and will help gauge the company's financial health this quarter.

Revenue

300M

Total revenue reflects the company's sales performance and growth potential, which is critical for investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Corcept achieve an EPS of $0.36 or higher?

This EPS figure is crucial for assessing the company's profitability and could influence investor sentiment significantly.

What is the revenue figure for this quarter, and how does it compare to the $300M consensus?

Revenue performance will indicate the company's sales strength and growth potential, which are vital for future projections.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Corcept's ability to rebound from recent earnings misses, as the company has a strong pipeline that could drive future growth.

Supporting Evidence

Despite recent misses, Corcept has consistently shown potential for recovery, as evidenced by its previous positive surprises.

The options market is pricing in a larger move than historical averages, suggesting that traders expect significant news.

The company's focus on cortisol-related treatments positions it well in a growing market segment.

Key Risk

If Corcept's revenue exceeds $300M, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is under scrutiny as it follows a series of mixed results, making it critical for Corcept to demonstrate solid growth.

Bull Confirmed If

An EPS of $0.36 or better, with revenue exceeding $300M, would confirm the bull case.

Bear Confirmed If

An EPS below $0.34 or revenue significantly under $268M would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±20.58%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±20.6% while CORT has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

58.0%

Calls (72K)P/C Ratio: 1.21Puts (21K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Corcept beats expectations, history suggests the stock could see a modest uptick, confirming positive market sentiment.

In-Line / Cautious

Should the results come in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

If the company misses expectations, history indicates a potential decline in stock price, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements or new drug approvals.
2Details on market demand for existing treatments and any competitive pressures.
3Management's commentary on cost management and profitability strategies.
4Insights into future growth plans and potential market expansions.
5Responses to any analyst questions regarding recent earnings performance.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

KRCAMC

Kilroy Realty Corporation

PreviewView

Jul27

PIIAMC

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will help gauge the company's financial health this quarter.

0.36

Revenue

Total revenue reflects the company's sales performance and growth potential, which is critical for investor confidence.

300M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CORT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.94%

Avg Stock Reaction

-0.00%

Last Quarter Recap

In Q1 2026, Corcept reported an EPS of -0.30, matching analyst expectations but showing no revenue figures. The stock reacted slightly negatively, declining by 0.15% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Corcept's upcoming earnings, with expectations for a modest profit and steady revenue growth.

Bull Case

If Corcept beats the EPS estimate and shows strong revenue growth, it could signal robust demand for its products, boosting investor confidence.

Bear Case

Conversely, if the company misses earnings expectations again, it could raise concerns about its growth trajectory and profitability.

Key Metrics to Watch

EPS

0.36

Earnings per share is a key indicator of profitability and will help gauge the company's financial health this quarter.

Revenue

300M

Total revenue reflects the company's sales performance and growth potential, which is critical for investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Corcept achieve an EPS of $0.36 or higher?

This EPS figure is crucial for assessing the company's profitability and could influence investor sentiment significantly.

What is the revenue figure for this quarter, and how does it compare to the $300M consensus?

Revenue performance will indicate the company's sales strength and growth potential, which are vital for future projections.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Corcept's ability to rebound from recent earnings misses, as the company has a strong pipeline that could drive future growth.

Supporting Evidence

Despite recent misses, Corcept has consistently shown potential for recovery, as evidenced by its previous positive surprises.

The options market is pricing in a larger move than historical averages, suggesting that traders expect significant news.

The company's focus on cortisol-related treatments positions it well in a growing market segment.

Key Risk

If Corcept's revenue exceeds $300M, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is under scrutiny as it follows a series of mixed results, making it critical for Corcept to demonstrate solid growth.

Bull Confirmed If

An EPS of $0.36 or better, with revenue exceeding $300M, would confirm the bull case.

Bear Confirmed If

An EPS below $0.34 or revenue significantly under $268M would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±20.58%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±20.6% while CORT has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

58.0%

Calls (72K)P/C Ratio: 1.21Puts (21K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Corcept beats expectations, history suggests the stock could see a modest uptick, confirming positive market sentiment.

In-Line / Cautious

Should the results come in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

If the company misses expectations, history indicates a potential decline in stock price, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements or new drug approvals.
2Details on market demand for existing treatments and any competitive pressures.
3Management's commentary on cost management and profitability strategies.
4Insights into future growth plans and potential market expansions.
5Responses to any analyst questions regarding recent earnings performance.